Global Gastrointestinal OTC Drugs Market, By Drug Class (Antacids, Laxatives, Anti-Diarrheal, Anti-Emetics, Others), Indications (Heartburn, Diarrhoea, Constipation, Gastroesophageal Reflux Disease (GERD Nausea, Vomiting, Motion Sickness, Others), End-Users (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Gastrointestinal OTC drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 7.20% in the above-mentioned research forecast period. Rising prevalence of gastrointestinal diseases or disorders and rising R&D activities globally for easily availability of OTC drugs.
However, technological advancement for self-diagnosis for gastrointestinal diseases and easy availability and cost effective of the OTC drugs also boost up the market growth. Moreover, rising demand for OTC drugs and rising population with gastrointestinal diseases in the developed as well as developing countries act as opportunity for the market growth. But, sometimes adverse effect related to the drugs, inadequate knowledge of the medication and stringent regulatory guidelines for the approval and commercialization of OTC drugs may hamper the global gastrointestinal OTC drugs market.
Gastrointestinal OTC is purchased without the doctor prescription that is anyone can purchase the medicine. Globally, half of the population suffering from some gastrointestinal diseases and so many peoples use over-the-counter (OTC) drugs to treat minor gastrointestinal problems. Moreover, OTC drugs are the first line treatment of any type of gastrointestinal diseases or disorders such as heartburn, gastroesophageal reflux disease (GERD) among others.
According to some Gastroenterology Research, approximately 40% population have some functional gastrointestinal disorders (FGIDs). It is estimated that alone in the U.S. 11% of population suffering from chronic digestive diseases, with a prevalence rate of 35% as high in older or geriatric population. It is also estimated that global OTC drugs market growing with 4.6% growth and having the size of USD 113,806 million in 2019.
This gastrointestinal OTC drugs market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Gastrointestinal OTC Drugs Market Scope and Market Size
Gastrointestinal OTC drugs market is segmented on the basis of drug class, indications, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug class, the gastrointestinal OTC drugs market is segmented antacids, laxatives, anti-diarrheal, anti-emetics and others. Antacids further segmented into proton pump inhibitors, H2 inhibitors, gastric acid neutralizers and others.
- On the basis of indications, the gastrointestinal OTC drugs market is segmented into heartburn, diarrhoea, constipation, gastroesophageal reflux disease (GERD) nausea, vomiting, motion sickness and others.
- On the basis of end-users, the gastrointestinal OTC drugs market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, the gastrointestinal OTC drugs market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Gastrointestinal OTC Drugs Market Country Level Analysis
Gastrointestinal OTC drugs market is analysed and market size information is provided by country, drug class, indications, end-users and distribution channel as referenced above.
The countries covered in the gastrointestinal OTC drugs market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the presence of high healthcare expenditure and favourable reimbursement policies for the treatment. Europe accounts the second largest market share due to increased genetic disorders and presence of refined medical facilities. Asia-Pacific is expected to account for the largest market share over coming years for the gastrointestinal OTC drugs market due to constant rise in the incidence of cancer coupled with increased demand for cost-efficient therapeutics.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Gastrointestinal OTC drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Gastrointestinal OTC Drugs Market Share Analysis
Gastrointestinal OTC drugs market competitive landscape provides details by competitor. details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to gastrointestinal OTC drugs market.
The major players covered in the gastrointestinal OTC drugs market are Mylan N.V. Sandoz AG, Johnson & Johnson Services, Inc., Sun Pharmaceuticals Industries Limited, Teva Pharmaceuticals Industries Ltd., Zydus Cadila, Sanofi, Bayer AG, Pfizer Inc., Abbott, Lupin, GlaxoSmithKline Plc., Prestige Brands, Inc., Procter & Gamble, Amneal Pharmaceutical Inc., Hikma Pharmaceutical PLC, Perrigo Pharmaceutical Plc., among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.